| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Ophthalmic Viscoelastic Devices Market Size 2024 |
USD 3163.51 Million |
| Ophthalmic Viscoelastic Devices Market, CAGR |
5.10% |
| Ophthalmic Viscoelastic Devices Market Size 2032 |
USD 4709.68 Million |
Market Overview
The Ophthalmic Viscoelastic Devices Market is expected to grow from USD 3163.51 million in 2024 to USD 4709.68 million by 2032, with a compound annual growth rate (CAGR) of 5.10%.
The Ophthalmic Viscoelastic Devices (OVD) market is primarily driven by advancements in ophthalmic surgical techniques and increasing prevalence of age-related eye disorders. Technological innovations such as the development of next-generation viscoelastic materials and enhanced surgical instrumentation are fostering market growth. Additionally, rising demand for minimally invasive procedures and the expanding elderly population contribute to the market’s upward trajectory. Moreover, the growing adoption of premium intraocular lenses (IOLs) in cataract surgeries further propels market expansion. Key trends include the emergence of combination OVDs and the integration of artificial intelligence (AI) in surgical planning, promising continued evolution and competitiveness in the OVD market landscape.
Geographical analysis reveals a robust presence of the Ophthalmic Viscoelastic Devices (OVD) market across regions, with North America and Europe leading due to established healthcare infrastructure and high adoption rates of advanced surgical procedures. The Asia-Pacific region showcases significant growth potential driven by expanding healthcare expenditure and a rising geriatric population. Key players dominating the market include Johnson & Johnson Vision Care, Inc., Carl Zeiss Meditec AG, Alcon Laboratories, Inc., Bausch & Lomb, and Rayner Surgical Group Ltd., with strategic initiatives such as mergers, acquisitions, and product launches strengthening their market foothold and fostering innovation in ophthalmic surgical solutions.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers
Rising Prevalence of Age-Related Eye Diseases
Globally, there’s a significant rise in age-related eye diseases like cataracts, glaucoma, and age-related macular degeneration (AMD). For instance, cataracts currently affect more than 24.4 million Americans over age 40, and by age 75, nearly 50% of all Americans will have cataracts. Age-related macular degeneration (AMD) affects 2.1 million Americans over age 50, and one in ten Americans will have AMD by the age of 80. Globally, there’s a significant rise in age-related eye diseases like cataracts, glaucoma, and AMD. These conditions often necessitate ophthalmic surgeries, where Ophthalmic Viscoelastic Devices (OVDs) play a crucial role. With an aging population, the prevalence of these diseases is escalating, driving up the demand for surgical interventions and associated products. In the United States alone, about 12 million people age 40 and above suffer from vision impairment, with about a million suffering from blindness. The statistics are just as concerning globally, with reports from the World Health Organization showing over 2.2 billion people with eye and vision problems.
Growing Geriatric Population Fuels Demand
The global population is aging, with a significant rise in the geriatric demographic most susceptible to eye diseases. For instance, the World Health Organization reports that between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%. By 2050, the world’s population of people aged 60 years and older will double to 2.1 billion. This demographic shift translates to a higher demand for ophthalmic surgeries, including cataract removals and intraocular lens implantations, which rely heavily on OVDs for optimal outcomes. As an example, the number of patients awaiting ophthalmic surgery for all subspecialties between 2010 to 2020 grew by 74%. The mean number of cases added per month between 2010 and 2020 increased by approximately 265 cases.
Increasing Number of Ophthalmic Surgeries
Advancements in surgical techniques are leading to a rise in the number of elective and necessary eye surgeries performed each year. For instance, the use of robots has revolutionized healthcare, wherein further innovations have led to improved precision and accuracy. Robotic surgery is feasible for numerous general surgical procedures, pending cost and operative time considerations, which will improve with technological advances. As optical imaging, robotics, and other high-tech advances contribute to greater precision and less invasive surgical techniques, the field is optimized to improve surgical outcomes by a significant measure in the near future. Growing awareness of ophthalmic treatments is also contributing to the increase in eye surgeries. For example, the World Health Organization (WHO) released a World Report on vision that stated there are over 2.2 billion people with vision impairment or blindness worldwide, and over 1 billion of those have conditions that could be treated or prevented. A total of 370 (88.7%) of them believed eye diseases can be prevented by regular check-ups from ophthalmologists.
Technological Advancements Drive Market Growth
The development of new OVDs with improved functionalities, including longer-lasting surgical protection, better biocompatibility, and targeted functionalities for specific surgical procedures, is propelling market growth. These technological advancements not only enhance surgical outcomes but also contribute to the efficiency and safety of ophthalmic procedures. With ongoing research and innovation, the OVD market continues to evolve, catering to the dynamic needs of ophthalmic surgeons and patients alike.
Market Trends
Advancements in OVD Technology
Manufacturers are increasingly prioritizing the use of biocompatible and sustainable materials in Ophthalmic Viscoelastic Devices (OVDs). This trend addresses concerns regarding patient safety and environmental impact. For instance, the interest in producing biodegradable polymers by chemical treatment, microorganisms, and enzymes has increased to make it easier to dispose of after the end of its use without harming the environment. Biodegradable polymers are being developed to be used as an alternative for non-biodegradable polymer materials in a variety of applications. OVDs made from natural polymers and biodegradable materials are being developed, aligning with sustainable practices while ensuring optimal patient outcomes. For example, bioplastics have been used for years in a number of medical channels, including for drug delivery via gelatin-based capsules, biodegradable stitches, and bio-based bandages to promote blood clotting and skin regeneration. The market is witnessing a surge in OVDs tailored for specific surgical applications, offering functionalities customized to different procedures. These targeted OVDs hold the potential to enhance surgical outcomes by providing specialized features. For instance, OVDs are integral to a wide range of ophthalmic surgeries because they can be used to create space, protect intraocular tissue, and facilitate surgical maneuvers. They are indispensable to cataract surgery; they can aid with capsulotomy creation and nuclear manipulation. They also have applications in cornea, glaucoma, retinal, pediatric, and strabismus surgeries and globe repair. Certain OVDs may offer extended protection for complex surgeries, while others may improve visibility during delicate procedures, thereby catering to diverse surgical needs with precision and efficacy. For example, a study showed that the postoperative mean endothelial cell loss was 14.4% and 7.1% from baseline in two different OVD groups, respectively. The incidence of intraocular pressure spikes at 2 hours was 0% and 8%, respectively. These statistics underscore the importance of selecting the right OVD for each specific surgical application.
Supporting Minimally Invasive Surgery
As minimally invasive ophthalmic surgery techniques gain momentum, OVDs are evolving to support these procedures effectively. Specifically designed OVDs may feature properties facilitating smaller incisions, enhanced visualization within the surgical site, and expedited post-operative recovery. This alignment with MIOS principles underscores the importance of OVD innovation in driving the adoption of less invasive surgical approaches in ophthalmology.
Market Challenges Analysis
Navigating Market Challenges in OVD Industry
The volatility in the cost of raw materials used in OVD production, such as hyaluronic acid and other polymers, poses a significant challenge. Fluctuations in raw material prices can impact production costs, potentially leading to price variations for OVDs. This dynamic environment affects both manufacturers and healthcare providers, requiring strategic management of procurement and pricing strategies to mitigate financial risks and maintain competitiveness in the market. The development and approval process for new OVDs are subject to stringent regulatory requirements, presenting a formidable challenge for manufacturers. Meeting these standards demands substantial investments of time and resources, potentially hindering innovation and delaying the introduction of new and improved OVD technologies to the market. Navigating the regulatory landscape requires meticulous planning and adherence to compliance protocols to ensure product safety and efficacy while expediting market entry.
Addressing Operational Constraints and Market Dynamics
The effective operation and handling of OVDs necessitate specialized training for ophthalmic surgeons and surgical staff. However, in some regions, there is a scarcity of adequately trained personnel, posing operational challenges. The limited availability of skilled labor can impede the utilization of advanced OVDs and potentially compromise surgical outcomes. Addressing this challenge requires investment in training programs and professional development initiatives to enhance surgical capabilities and ensure optimal utilization of OVD technologies. Despite reimbursement policies covering OVDs in ophthalmic surgeries, obtaining adequate reimbursement for these devices can be complex. This reimbursement ambiguity poses challenges for hospitals and surgery centers, potentially discouraging the adoption of the latest OVD technologies. Overcoming reimbursement hurdles requires proactive engagement with payers, advocating for fair reimbursement policies, and demonstrating the clinical and economic value of advanced OVDs to secure adequate compensation and foster market growth.
Market Segmentation Analysis:
By Product Type:
The Ophthalmic Viscoelastic Devices (OVD) market is segmented by product type into cohesive and dispersive ophthalmic viscoelastics. Cohesive ophthalmic viscoelastics maintain a cohesive gel-like consistency, providing excellent space maintenance and protecting delicate ocular tissues during surgeries. These viscoelastics are commonly used in cataract surgeries and other intraocular procedures requiring stable anterior chamber maintenance. Dispersive ophthalmic viscoelastics, on the other hand, have a more viscous consistency and spread over the corneal endothelium, facilitating tissue manipulation and preventing endothelial cell damage. They are particularly suitable for procedures involving delicate tissue manipulation, such as glaucoma surgeries and corneal transplants. The choice between cohesive and dispersive viscoelastics depends on the surgical requirements and preferences of the ophthalmic surgeon, with each type offering distinct advantages in specific surgical scenarios.
By Application:
The OVD market is further segmented based on application into cataract surgery, glaucoma surgery, and corneal transplant procedures. Cataract surgery represents the largest segment, driven by the increasing prevalence of cataracts globally and the growing demand for minimally invasive surgical techniques. OVDs play a crucial role in cataract surgery by maintaining intraocular space, protecting ocular structures, and facilitating efficient phacoemulsification. Glaucoma surgery, aimed at reducing intraocular pressure to prevent optic nerve damage, also relies on OVDs for optimal surgical outcomes. Additionally, corneal transplant procedures, which involve replacing damaged or diseased corneal tissue with healthy donor tissue, benefit from the use of OVDs to protect the corneal endothelium and ensure successful graft integration. The diverse applications of OVDs underscore their importance across a wide range of ophthalmic surgical procedures, contributing to the overall growth and stability of the OVD market.
Segments:
Based on Product Type
- Cohesive Ophthalmic Viscoelastic
- Dispersive Ophthalmic Viscoelastic
Based on Application
- Cataract
- Glaucoma
- Corneal Transplant
Based on the Geography
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis
North America
North America currently holds the largest market share, accounting for approximately 35% of the global ophthalmic viscoelastic devices market. The region’s well-established healthcare infrastructure, the presence of major industry players, and the high adoption rate of innovative ophthalmic technologies have contributed to its dominant position. The United States, in particular, has been at the forefront of adopting advanced ophthalmic viscoelastic devices for cataract surgeries, vitreoretinal procedures, and other surgical interventions related to the eye.
Europe
Europe follows closely behind, with a market share of around 30%. Countries like Germany, France, and the United Kingdom have been proactive in promoting eye health and the adoption of advanced ophthalmic surgical techniques. The region’s focus on improving patient outcomes, reducing healthcare costs associated with vision impairment, and the availability of cutting-edge ophthalmic viscoelastic devices have fueled market growth. Additionally, the increasing geriatric population and the rising incidence of age-related eye diseases have further boosted the demand for reliable ophthalmic viscoelastic solutions in Europe.
Key Player Analysis
- Bausch Health Companies, Inc.
- Bohus Biotech Ab
- Johnson & Johnson
- Novartis International AG
- Eyekon Medical Inc.
- Carl Zeiss Meditec AG
- Cima Technology Inc.
- Rumex International Corporation
- Haohai Biological Technology
- Altacor
Competitive Analysis
The Ophthalmic Viscoelastic Devices (OVD) market features several leading players vying for market share through innovation, product differentiation, and strategic initiatives. Bausch Health Companies, Inc., a key player, leverages its extensive product portfolio and global presence to maintain a competitive edge. Johnson & Johnson and Novartis International AG are prominent contenders, known for their strong R&D capabilities and continuous investment in advanced ophthalmic technologies. Carl Zeiss Meditec AG stands out for its cutting-edge surgical equipment and integrated solutions, complementing its OVD offerings. Eyekon Medical Inc. and Rumex International Corporation focus on niche segments, offering specialized OVD solutions tailored to specific surgical requirements. Bohus Biotech Ab, Cima Technology Inc., Haohai Biological Technology, and Altacor also contribute to market competitiveness with their diverse product offerings and strategic partnerships. The competitive landscape underscores the importance of product innovation, clinical efficacy, and market expansion strategies in driving growth and maintaining leadership positions in the OVD market.
Recent Developments
In Jan 2022,The U.S. Food and Drug Administration (FDA) has granted the 510(k) clearance for Glaukos Corporation’s iPRIMETM Viscodelivery System, a sterile, single-use, minimally invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. The company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
In April 2022, Bausch & Lomb Incorporated, an eye health products company, announced the launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System in the U.S. Through this move, the company intended to expand its product offering and strengthen its regional customer base.
Market Concentration & Characteristics
The Ophthalmic Viscoelastic Devices (OVD) market exhibits a moderate level of market concentration characterized by the presence of several key players dominating the industry. While there are numerous manufacturers and suppliers operating within the market, a handful of companies such as Bausch Health Companies, Inc., Johnson & Johnson, and Novartis International AG hold significant market shares. These leading players leverage their extensive product portfolios, strong distribution networks, and robust R&D capabilities to maintain competitive positions. Market concentration is further enhanced by high entry barriers, including stringent regulatory requirements, substantial R&D investments, and the need for specialized manufacturing capabilities. Additionally, the market is characterized by continuous technological advancements, with players focusing on developing innovative OVD formulations, enhancing surgical techniques, and expanding their geographic reach to capitalize on emerging opportunities. Overall, the OVD market’s concentration reflects a competitive landscape driven by innovation, strategic partnerships, and a commitment to delivering high-quality products to meet evolving ophthalmic surgical needs.
Report Coverage
The research report offers an in-depth analysis based on Product Type, Application, and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Future Outlook
- The Ophthalmic Viscoelastic Devices (OVD) market is poised for steady growth driven by the rising prevalence of age-related eye diseases globally.
- Technological advancements will continue to shape the market, with a focus on developing biocompatible and sustainable materials for OVD production.
- Increasing demand for minimally invasive ophthalmic surgeries will drive the development of OVDs tailored to support these procedures.
- Market players will invest in research and development to introduce targeted OVD formulations optimized for specific surgical applications.
- Regulatory compliance will remain a key consideration, influencing product development and market entry strategies.
- Geographic expansion and strategic collaborations will enable companies to tap into emerging markets and strengthen their market presence.
- Growing adoption of outpatient eye surgery centers will create opportunities for OVD manufacturers to innovate products suited for these settings.
- Integration of advanced technologies like hydrogels with OVDs will enhance surgical outcomes and patient care.
- Market consolidation may occur as companies seek to streamline operations and leverage synergies to gain a competitive edge.
- Education and awareness initiatives will play a crucial role in driving market growth, particularly in developing regions, to ensure optimal utilization of OVDs in ophthalmic surgeries.
